C_8 cycloalkyl or phenyl; or R^3 is a C-linked, 5- to 7-membered ring monocyclic heterocycle having either from 1 to 4 ring nitrogen atom(s) or 1 or 2 nitrogen and 1 oxygen or 1 sulphur ring atoms, optionally C-substituted by oxo, C_1-C_6 alkoxy(C_1-C_6)alkyl, $R^6R^6N(C_1$-$C_6)$alkyl, halo(C_1-C_6)alkyl, fluoro(C_1-C_6)alkoxy, fluoro(C_2-C_5)alkanoyl, halo, cyano, OR^6, R^7, COR^6, $-NR^6R^6$, $-COOR^6$, $-S(O)_mR^7$, $-SO_2NR^6R^6$, $-CONR^6R^6$, $-NR^6SO_2R^7$ or $-NR^6COR^7$ and optionally N-substituted by C_1-C_6 alkoxy(C_1-C_6)alkyl, $R^6R^6N(C_2$-$C_6)$alkyl, halo(C_1-C_6)alkyl, fluoro(C_2-C_5)alkanoyl, R^7, $-COR^6$, $-COOR^7$, $-SO_2R^7$, $-SO_2NR^6R^6$ or $-CONR^6R^6$; or, when A is C_2-C_6 alkylene, R^3 is N-linked pyrrolidinyl, piperidinyl or morpholinyl, each being optionally C-substituted by C_1-C_6 alkyl, phenyl, C_1-C_6 alkoxy(C_1-C_6)alkyl, $R^4R^4N(C_1$-$C_6)$alkyl, halo(C_1-C_6)alkyl, fluoro(C_1-C_6)alkoxy, C_2-C_5 alkanoyl, halo, $-OR^4$, cyano, $-COOR^4$, C_3-C_8 cycloalkyl, $-S(O)_mR^5$, $-NR^4R^4$, $-SO_2NR^4R^4$, $-CONR^4R^4$, $-NR^4COR^5$ or $-NR^4SO_2R^5$.

9. (Amended) A compound as claimed in claim 8 wherein R^3 is phenyl; or, when A is C_2-C_6 alkylene, R^3 is $-NR^4R^4$ wherein R^4 is C_1-C_6 alkyl; or, R^3 is a C-linked, 5- or 6-membered ring monocyclic aromatic heterocycle having from 1 to 4 ring nitrogen atom(s), optionally C-substituted by oxo, C_1-C_6 alkoxy(C_1-C_6)alkyl, $R^6R^6N(C_1$-$C_6)$alkyl, halo(C_1-C_6)alkyl, fluoro(C_1-C_6)alkoxy, fluoro(C_2-C_5)alkanoyl, halo, cyano, $-OR^6$, R^7, $-COR^6$, $-NR^6R^6$, $-COOR^6$, $-S(O)_mR^7$, $-SO_2NR^6R^6$, $-CONR^6R^6$, $-NR^6SO_2R^7$ or $-NR^6COR^7$ and optionally N-substituted by C_1-C_6 alkoxy(C_1-C_6)alkyl, $R^6R^6N(C_2$-$C_6)$alkyl, halo(C_1-C_6)alkyl, fluoro(C_2-C_5)alkanoyl, R^7, $-COR^6$, $-COOR^7$, $-SO_2R^7$, $-SO_2NR^6R^6$ or $-CONR^6R^6$; or, when A is C_2-C_6 alkylene, R^3 is N-linked pyrrolidinyl, piperidinyl or morpholinyl, each being optionally C-substituted by C_1-C_6 alkyl or $-OR^4$ wherein R^4 is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl or phenyl.

B2 B concld

10. (Amended) A compound as claimed in claim 9 wherein R^3 is phenyl; or, when A is C_2-C_6 alkylene, R^3 is $-N(CH_3)_2$; or R^3 is C-linked pyridinyl optionally substituted by $-OR^6$, R^7, C_1-C_6 alkoxy(C_1-C_6)alkyl, $R^6R^6N(C_1$-$C_6)$alkyl or $-NR^6R^6$ wherein R^6 is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, naphthyl or het and R^7 is C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, naphthyl or het; or when A is C_2-C_6 alkylene, R^3 is pyrrolidin-1-yl, piperidin-1-yl, 4-isopropylpiperidin-1-yl or morpholin-4-yl.

B3

13. (Amended) A compound as claimed in claim 1 wherein -A-R^3 is phenethyl, 2-(dimethylamino)ethyl, 2-pyridinylmethyl, 2-(2-pyridinyl)ethyl, 3-(1-pyrrolidinyl)propyl, 2-(1-piperidinyl)ethyl, 2-(4-isopropyl-1-piperidinyl)ethyl or 2-(4-morpholinyl)ethyl.

B4

18. (Amended) A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable excipient, diluent or carrier.

B5

25. (Amended) A method of agonising an A2a receptor in a mammal comprising administering to said mammal in need of such treatment an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

26. (Amended) A method of treating an inflammatory disease in a mammal comprising administering to said mammal an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

27. (Amended) A method of treating a respiratory disease in a mammal comprising administering to said mammal an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

B6

29. (Amended) A method of treating septic shock, male erectile dysfunction, hypertension, stroke, epilepsy, cerebral ischaemia, peripheral vascular disease, post-ischaemic reperfusion injury, diabetes, rheumatoid arthritis, multiple sclerosis, psoriasis, dermatitis, allergic dermatitis, eczema, ulcerative colitis, Crohns disease, inflammatory bowel disease, *Heliobacter pylori* gastritis, non-*Heliobacter pylori* gastritis, non-steroidal anti-inflammatory drug-induced damage to the gastro-intestinal tract or a psychotic disorder, or for wound healing in a mammal comprising administering to said mammal in need of such treatment an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

B7

31. (Amended) A compound of the formula:



(II)

wherein X is a leaving group such as bromo, iodo, -Sn(C_1-C_{12} alkyl)$_3$ or CF_3SO_2O-, with the proviso that when X is bromo or iodo, R^1 is not H; or



(VI)

wherein R^8 and R^9, when taken separately, are protecting groups, or, when taken together, are a protecting group; or



(X)

wherein R^8 and R^9, when taken separately, are protecting groups, or, when taken together, are a protecting group, and R^{10} is a protecting group; or



(IX)

wherein R^8 and R^9, when taken separately, are protecting groups, or, when taken together, are a protecting group, and R^{10} is a protecting group, with the proviso when R^1 is H, that R^8, R^9 and R^{10} are not each t-butyldimethylsilyl or acetyl; or



(XII)

wherein R^{11}, R^{12} and R^{13}, taken separately, are protecting groups, or R^{11} is a protecting group and R^{12} and R^{13}, taken together, are a protecting group; or



(XIII)

; or

B7 cont'd



(XXI)

wherein R^{14} is a protecting group; or



(XXII)

wherein R^{14} is a protecting group,

R^1 is hydrogen or C_1-C_6 alkyl optionally substituted by 1 or 2 substituents each independently selected from phenyl and naphthyl, said phenyl and naphthyl being optionally substituted by C_1-C_6 alkyl, C_1-C_6 alkoxy, halo or cyano;

R^2 is H or C_1-C_6 alkyl;

A is C_1-C_6 alkylene;

R^3 is (i) hydrogen, C_1-C_6 alkyl, -$COOR^4$, -CN, –$CONR^4R^4$, C_3-C_8 cycloalkyl, phenyl or naphthyl, said C_3-C_8 cycloalkyl, phenyl and naphthyl being optionally substituted by C_1-C_6 alkyl, phenyl, C_1-C_6 alkoxy(C_1-C_6)alkyl, $R^4R^4N(C_1$-$C_6)$alkyl, halo(C_1-C_6)alkyl, fluoro(C_1-C_6)alkoxy, C_2-C_5 alkanoyl, halo, -OR^4, cyano, -$COOR^4$, C_3-C_8 cycloalkyl, -$S(O)_mR^5$, -NR^4R^4, -$SO_2NR^4R^4$, -$CONR^4R^4$, -NR^4COR^5 or -$NR^4SO_2R^5$,

or (ii) when A is C_2-C_6 alkylene, -NR^4R^4, -OR^4, -$OCOR^5$, -SO_2R^5, -$SO_2NR^4R^4$ or -NR^4COR^5,

or (iii) a C-linked, 4- to 11-membered ring, mono- or bicyclic, heterocycle having either from 1 to 4 ring nitrogen atom(s), or 1 or 2 nitrogen and 1 oxygen or 1 sulphur ring atoms, being optionally C-substituted by oxo, C_1-C_6 alkoxy(C_1-C_6)alkyl, $R^6R^6N(C_1$-$C_6)$alkyl, halo(C_1-C_6)alkyl, fluoro(C_1-C_6)alkoxy, fluoro(C_2-C_5)alkanoyl, halo, cyano, -OR^6, R^7, -COR^6, -NR^6R^6, -$COOR^6$, -$S(O)_mR^7$,

B7 cont'd

$-SO_2NR^6R^6$, $-CONR^6R^6$, $-NR^6SO_2R^7$ or $-NR^6COR^7$ and optionally N-substituted by C_1-C_6 alkoxy(C_1-C_6)alkyl, $R^6R^6N(C_2$-$C_6)$alkyl, halo(C_1-C_6)alkyl, fluoro(C_2-C_5)alkanoyl, R^7, $-COR^6$, $-COOR^7$, $-SO_2R^7$, $-SO_2NR^6R^6$ or $-CONR^6R^6$,

or (iv) when A is C_2-C_6 alkylene, N-linked azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl or morpholinyl, each being optionally C-substituted by C_1-C_6 alkyl, phenyl, C_1-C_6 alkoxy(C_1-C_6)alkyl, $R^4R^4N(C_1$-$C_6)$alkyl, halo(C_1-C_6)alkyl, fluoro(C_1-C_6)alkoxy, C_2-C_5 alkanoyl, halo, $-OR^4$, cyano, $-COOR^4$, C_3-C_8 cycloalkyl, $-S(O)_mR^5$, $-NR^4R^4$, $-SO_2NR^4R^4$, $-CONR^4R^4$, $-NR^4COR^5$ or $-NR^4SO_2R^5$, and said piperazinyl and homopiperazinyl being optionally N-substituted by C_1-C_6 alkyl, phenyl, C_1-C_6 alkoxy(C_2-C_6)alkyl, $R^4R^4N(C_2$-$C_6)$alkyl, fluoro(C_1-C_6)alkyl, C_2-C_5 alkanoyl, $-COOR^5$, C_3-C_8 cycloalkyl, $-SO_2R^5$, $-SO_2NR^4R^4$ or $-CONR^4R^4$;

R^4 is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl or phenyl;

R^5 is C_1-C_6 alkyl, C_3-C_8 cycloalkyl or phenyl;

R^6 is H, C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, naphthyl or het;

R^7 is C_1-C_6 alkyl, C_3-C_8 cycloalkyl, phenyl, naphthyl or het;

m is 0, 1 or 2; and

"het", used in the definitions of R^6 and R^7, means C-linked pyrrolyl, imidazolyl, triazolyl, thienyl, furyl, thiazolyl, oxazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, quinolinyl, isoquinolinyl, benzimidazolyl, quinazolinyl, phthalazinyl, benzoxazolyl or quinoxalinyl, each being optionally substituted by C_1-C_6 alkyl, C_1-C_6 alkoxy, cyano or halo.

B7 concld

NE not in compliant

33. (Amended) A compound as claimed in claim 31 ~~and 32~~ wherein R^1 is 2,2-diphenylethyl, R^2 is H and/or $-A-R^3$ is 2-(1-piperidinyl)ethyl.

Cancel claims 19 - 24, without waiver or prejudice.

Add the following new claims:

B8

41. (New) ~~A method~~ of any one of claims 25 - 29 wherein said mammal is a human.

42. (New) A compound as claimed in claim 32 wherein R^1 is 2,2-diphenylethyl, R^2 is H and/or -A-R^3 is 2-(1-piperidinyl)ethyl.

-Remarks-

The claims were amended to cancel claims 19 - 24 as being directed to non-statutory claim types in the United States. Claims 4, 5, 8 - 10, 13, 18, 25 - 27, 29, 31 and 33 were amended primarily to remove claims which were multiply dependent upon